upcarta
  • Sign In
  • Sign Up
  • Explore
  • Search

Wreck-fidera: How Medicare Part D has hidden the benefits of generic competition for a blockbuster Multiple Sclerosis treatment — 46brooklyn Research

  • Article
  • Dec 1, 2021
  • #Biotechnology
46brooklyn Research
@46brooklyndata
(Author)
www.46brooklyn.com
Read on www.46brooklyn.com
1 Recommender
1 Mention
Roughly two years ago, we put on our hardhats and went spelunking into the cavernous depths of the byzantine Medicare Part D plan cost share world to better understand and illustrat... Show More

Roughly two years ago, we put on our hardhats and went spelunking into the cavernous depths of the byzantine Medicare Part D plan cost share world to better understand and illustrate how the incentives created by the program’s design were bewilderingly injecting life into multi-source brands (i.e., “zombie brands”) and leading to warped, inflated pricing (and poor uptake) of their generic equivalents. We ventured down into these depths using Teva’s Copaxone as our case study, a blockbuster drug that treats certain types of multiple sclerosis (MS), and is no stranger to drama when it comes to pricing issues and patent games.

Show Less
Recommend
Post
Save
Complete
Collect
Mentions
See All
Nikhil Krishnan @nikillinit · Jan 17, 2022
  • Post
  • From Twitter
this is a great read from @46brooklyndata on the failures of medicare part D's prescription drug benefit design using Tecifidera (an MS drug) as a case study for when generics enter the market and get prevented from being used some damning points:
  • upcarta ©2025
  • Home
  • About
  • Terms
  • Privacy
  • Cookies
  • @upcarta